{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:37:51Z","timestamp":1790134671098,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81422044"],"award-info":[{"award-number":["81422044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673362"],"award-info":[{"award-number":["81673362"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.actbio.2017.05.009","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T22:16:35Z","timestamp":1494022595000},"page":"114-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Combined delivery of a TGF-\u03b2 inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy"],"prefix":"10.1016","volume":"61","author":[{"given":"Jiayu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.actbio.2017.05.009_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2013.09.016","article-title":"A personalized view on cancer immunotherapy","volume":"352","author":"Wayteck","year":"2013","journal-title":"Cancer Lett."},{"issue":"27","key":"10.1016\/j.actbio.2017.05.009_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy for cancer","volume":"27","author":"Dougan","year":"2009","journal-title":"Annu. Rev. Immunol."},{"issue":"7378","key":"10.1016\/j.actbio.2017.05.009_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.actbio.2017.05.009_b0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2017.05.009_b0025","article-title":"Opinion: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"805\u2013812","author":"Allison","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng1001-117","article-title":"TGF-beta signaling in tumor suppression and cancer progression","volume":"29","author":"Derynck","year":"2001","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.actbio.2017.05.009_b0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.leu.2401477","article-title":"Effects of TGF-beta on the immune system: implications for cancer immunotherapy","volume":"13","author":"de Visser","year":"1999","journal-title":"Leukemia"},{"issue":"18 Pt 1","key":"10.1016\/j.actbio.2017.05.009_b0040","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","article-title":"Transforming growth factor-\u03b2 and the immune response: implications for anticancer therapy","volume":"13","author":"Wrzesinski","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.actbio.2017.05.009_b0045","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGF\u03b2","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2017.05.009_b0050","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1182\/blood.V93.5.1448","article-title":"Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-\u03b2: relationship with IL-12 signaling","volume":"93","author":"Pardoux","year":"1999","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.actbio.2017.05.009_b0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.immunol.16.1.137","article-title":"Regulation of immune responses by TGF-beta","volume":"16","author":"Letterio","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.actbio.2017.05.009_b0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-002-0356-5","article-title":"IL-12: a promising adjuvant for cancer vaccination","volume":"52","author":"Portielje","year":"2003","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.actbio.2017.05.009_b0065","unstructured":"A.Y.A. Kutikhin, Interleukin-12 Superfamily and Cancer, 260 ed., 2015."},{"issue":"4","key":"10.1016\/j.actbio.2017.05.009_b0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0075","first-page":"96","article-title":"Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer","volume":"2","author":"Tahara","year":"1995","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.actbio.2017.05.009_b0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/CJI.0b013e318031a2b2","article-title":"Enhancing antitumor immunity: Combining IL-12 with TGF\u03b21 antagonism","volume":"30","author":"Fan","year":"2007","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.actbio.2017.05.009_b0085","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/mol.65.3.744","article-title":"SB-505124 is a selective inhibitor of transforming growth factor-\u03b2 type I receptors ALK4, ALK5, and ALK7","volume":"65","author":"Byfield","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.actbio.2017.05.009_b0090","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.actbio.2017.05.009_b0095","first-page":"3983","article-title":"Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer","volume":"5","author":"Portielje","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0167-5699(94)90131-7","article-title":"Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?","volume":"15","author":"Colombo","year":"1994","journal-title":"Immunol. Today"},{"issue":"21","key":"10.1016\/j.actbio.2017.05.009_b0105","first-page":"4765","article-title":"High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12","volume":"55","author":"Meko","year":"1995","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jconrel.2009.10.027","article-title":"Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure","volume":"142","author":"Suzuki","year":"2010","journal-title":"J. Control. Release"},{"issue":"36","key":"10.1016\/j.actbio.2017.05.009_b0115","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","article-title":"Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma","volume":"26","author":"Daud","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.actbio.2017.05.009_b0120","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors","volume":"22","author":"Bruno","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1(20)","key":"10.1016\/j.actbio.2017.05.009_b0125","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1038\/sj.gt.3302619","article-title":"Adenovirus as vehicle for anticancer genetic immunotherapy","volume":"12","author":"Gallo","year":"2005","journal-title":"Gene Ther."},{"issue":"5304","key":"10.1016\/j.actbio.2017.05.009_b0130","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.actbio.2017.05.009_b0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ijc.20129","article-title":"Modified adenoviruses for cancer gene therapy","volume":"110","author":"Kanerva","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.actbio.2017.05.009_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications","volume":"132","author":"Hartman","year":"2008","journal-title":"Virus Res."},{"issue":"5","key":"10.1016\/j.actbio.2017.05.009_b0145","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1089\/10430349950018535","article-title":"Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection","volume":"10","author":"Diebold","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"1\u20132","key":"10.1016\/j.actbio.2017.05.009_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.044","article-title":"Cyclodextrins and their pharmaceutical applications","volume":"329","author":"Loftsson","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.actbio.2017.05.009_b0155","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.actbio.2017.05.009_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/mp900151k","article-title":"Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells","volume":"7","author":"Zhong","year":"2010","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2011.03.013","article-title":"Highly efficient nanomedicines assembled via polymer-drug multiple interactions: tissue-selective delivery carriers","volume":"152","author":"Zhu","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2017.05.009_b0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpba.2015.09.002","article-title":"Development and validation of an LC\u2013MS\/MS method for the determination of SB-505124 in rat plasma: Application to pharmacokinetic study","volume":"117","author":"Jiang","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.actbio.2017.05.009_b0175","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jgm.874","article-title":"Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system","volume":"8","author":"Tang","year":"2006","journal-title":"J. Gene Med."},{"issue":"3","key":"10.1016\/j.actbio.2017.05.009_b0180","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/mthe.2001.0329","article-title":"Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages","volume":"3","author":"Zhang","year":"2001","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.actbio.2017.05.009_b0185","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1016\/j.biomaterials.2013.03.004","article-title":"Therapeutic efficacy of a systemically delivered oncolytic adenovirus-biodegradable polymer complex","volume":"34","author":"Jaesung","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2017.05.009_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/path.4530","article-title":"A novel profibrotic mechanism mediated by TGF \u03b2-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells","author":"Luo","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.actbio.2017.05.009_b0195","series-title":"The Experimental Animal and Animal Experimental Technology","author":"Miao","year":"1997"},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(90)90155-8","article-title":"TGF-\u03b2 stimulation and inhibition of cell proliferation: new mechanistic insights","volume":"63","author":"Moses","year":"1990","journal-title":"Cell"},{"issue":"49","key":"10.1016\/j.actbio.2017.05.009_b0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0092-8674(87)90443-0","article-title":"The TGF-\u03b2 family of growth and differentiation factors","volume":"49","author":"Massagu\u00e9","year":"1987","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.actbio.2017.05.009_b0210","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-\u03b2 signal transduction","volume":"67","author":"Massagu\u00e9","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.actbio.2017.05.009_b0215","doi-asserted-by":"crossref","first-page":"F816","DOI":"10.1152\/ajprenal.00024.2005","article-title":"Reactive oxygen species production via NADPH oxidase mediates TGF-\u03b2-induced cytoskeletal alterations in endothelial cells","volume":"289","author":"Hu","year":"2005","journal-title":"Am. J. Physiol.-Renal Physiol."},{"key":"10.1016\/j.actbio.2017.05.009_b0220","first-page":"1880","article-title":"Suppression of transforming growth factor-\u03b2 effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor","volume":"16","author":"Sapitro","year":"2010","journal-title":"Mol. Vision."},{"issue":"11","key":"10.1016\/j.actbio.2017.05.009_b0225","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0962-8924(01)02130-4","article-title":"TGF-\u03b2 signaling in cancer\u2013a double-edged sword","volume":"11","author":"Akhurst","year":"2001","journal-title":"Trends Cell Biol."},{"issue":"3","key":"10.1016\/j.actbio.2017.05.009_b0230","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.4049\/jimmunol.1000425","article-title":"IL-12p35 promotes antibody-induced joint inflammation by activating NKT cells and suppressing TGF-beta","volume":"185","author":"Park","year":"2010","journal-title":"Journal of Immunology."},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00049409","article-title":"Cell adhesion receptor expression during melanoma progression and metastasis","volume":"10","author":"Hart","year":"1991","journal-title":"Cancer Metastasis Rev."},{"issue":"12","key":"10.1016\/j.actbio.2017.05.009_b0240","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/nrd1580","article-title":"Development of TGF-beta signalling inhibitors for cancer therapy","volume":"3","author":"Yingling","year":"2004","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"5","key":"10.1016\/j.actbio.2017.05.009_b0245","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/BF00121916","article-title":"Inhibition of cancer cell motility and invasion by interleukin-12","volume":"13","author":"Hiscox","year":"1995","journal-title":"Clin. Exp. Metastasis"},{"issue":"2","key":"10.1016\/j.actbio.2017.05.009_b0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.actbio.2017.05.009_b0255","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1440-1746.2003.03295.x","article-title":"Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12","volume":"19","author":"Peron","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.actbio.2017.05.009_b0260","article-title":"IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma","volume":"5","author":"Lee","year":"2002","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"1","key":"10.1016\/j.actbio.2017.05.009_b0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1084\/jem.183.1.147","article-title":"The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells","volume":"183","author":"Ma","year":"1996","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.actbio.2017.05.009_b0270","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1073\/pnas.0611660104","article-title":"Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling","volume":"104","author":"Kano","year":"2007","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706117302921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706117302921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:59:56Z","timestamp":1761670796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706117302921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":54,"alternative-id":["S1742706117302921"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2017.05.009","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined delivery of a TGF-\u03b2 inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2017.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}